

To: [REDACTED] [REDACTED] [REDACTED] [REDACTED] [REDACTED]
[REDACTED] [REDACTED] [REDACTED] [REDACTED] [REDACTED]
[REDACTED] [REDACTED] [REDACTED] [REDACTED] [REDACTED]
From: [REDACTED]
Sent: Thur 11/19/2020 9:50:17 PM
Subject: RE: Arthritis drug shows promise in treating sickest COVID-19patients
Received: Thur 11/19/2020 9:50:18 PM

Ha 5.1.2e

Zeker gezien. Goed om voorraden te laten checken. Ik begreep uit berichtgeving dat er voldoende voorraad zou zijn, maar een goede check vanuit ons lijkt me zeker geen overbodige luxe.

Ik mail je zo nog even de mailwisseling met woordvoering over dit nieuws van eerder vandaag.

Groet

Verzonden met BlackBerry Work
(www.blackberry.com)

Van: 5.1.2e <5.1.2e@minvws.nl>
Datum: donderdag 19 nov. 2020 9:55 PM
Aan: 5.1.2e <5.1.2e@minvws.nl>, 5.1.2e <5.1.2e@minvws.nl>, 5.1.2e <5.1.2e@minvws.nl>, 5.1.2e <5.1.2e@minvws.nl>, 5.1.2e <5.1.2e@minvws.nl>
Onderwerp: FW: Arthritis drug shows promise in treating sickest COVID-19 patients

Wellicht ook dit bericht gezien? Was ook op NOS.
Wellicht de voorraden van dit middel laten checken door LCG?

Van: POLITICO Pro Health Care Alert <5.1.2e@politico.eu>
Verzonden: donderdag 19 november 2020 18:18
Aan: 5.1.2e <5.1.2e@minvws.nl>
Onderwerp: Arthritis drug shows promise in treating sickest COVID-19 patients

Arthritis drug shows promise in treating sickest COVID-19 patients

-- By 5.1.2e
November 19, 2020, 6:17 pm | [View in your browser](#)

Early [results](#) from an international trial have shown that critically ill COVID-19 patients treated with the arthritis drug tocilizumab are significantly more likely to have improved outcomes.

This was measured by patients' need for breathing support and their survival rates, compared to patients who received no immune modulator therapy.

The findings — from the [REMAP-CAP trial](#), led by Imperial College London and the Intensive Care National Audit & Research Centre (ICNARC) — are not yet peer reviewed. And the authors note the relative contribution of survival rates and reduced length of time needing organ support in intensive care has not yet been analyzed.

The same trial found that **dexamethasone** improves survival in some COVID-19 patients.

"This is fantastic news," said U.K. Health Secretary Matt Hancock. "We will keep working closely with the company to ensure NHS patients can access the medicine now."

Scientists welcomed the news but expressed caution, noting two recent randomized controlled trials didn't show benefits in patients treated with tocilizumab. However, one other trial, published in JAMA recently, did.

"Results on the use of [steroids](#) in severe COVID have provided proof of principle that anti-inflammatory drug can help, so this is an encouraging result which suggests that other, more targeted, anti-inflammatory drugs may also help," said [5.1.2e](#), [5.1.2e](#) University of Oxford. But he noted overall that study results have been mixed.

"It is likely that tocilizumab will benefit some patients," said [5.1.2e](#) [5.1.2e](#) [5.1.2e](#) University of Bristol. "What is still not clear is how we identify the patient population with COVID-19 which is likely to benefit from tocilizumab."

Related stories on these topics: [Clinical trials](#), [Coronavirus](#), [Drug and device safety](#), [Hospitals](#), [Infectious diseases](#), [Medicines](#), [Patients](#), [Pharma](#), [Regulation](#), [Matt Hancock](#), [U.K. National Health Service \(NHS\)](#)

To update your POLITICO Pro notification preferences, visit www.politico.eu/notification

** Tell us what you think: Was this Pro content helpful? [Yes](#) | [No](#) **

View the Pro calendar at www.politico.eu/calendar. Submit an event [here](#).

This email alert has been sent for your exclusive use as a POLITICO Pro subscriber. Forwarding or reproducing the alert without the express, written permission of POLITICO Pro is a violation of the POLITICO Pro license agreement.

This email was sent to [5.1.2e](#) [@minvws.nl](#)
[Adjust your Pro subscription settings](#), or
[unsubscribe from all POLITICO SRL emails](#)
POLITICO SRL · Rue de la Loi 62 · Brussels 1040 · Belgium